Location Directory

Clinical trials in Nashville, Tennessee

This page shows live ClinicalTrials.gov search results for Nashville, Tennessee, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

10880

Shown on this page

Current sort

Institutions in Nashville

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Vanderbilt University Medical Center

Live official records

Open in full search

Conditions: Stress Urinary Incontinence (SUI)
Interventions: Artificial Urinary Sphincter (AUS); Device
Lead sponsor: UroMems SAS; Industry
Eligibility: 22 Years and older · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 9 more

Conditions: Depression
Interventions: Cognitive behavioral therapy plus social cognitive training (CBTSCT); Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 13 Years to 17 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2-low Breast Cancer
Interventions: CGT6297; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 9 more

Conditions: Locally Advanced or Metastatic Malignant Solid Tumors
Interventions: ASP2998, Pembrolizumab, Enfortumab Vedotin, Carboplatin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Celebration, Florida • Hackensack, New Jersey • New Hyde Park, New York + 2 more

Conditions: Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions: Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Radiation Therapy, Sigmoidoscopy, Total Mesorectal Excision; Procedure · Biological · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 213
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 145 more

Conditions: Endometrial Cancer
Interventions: Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 57
States / cities: Little Rock, Arkansas • Duarte, California • La Jolla, California + 50 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Entinostat, Exemestane, Goserelin, Goserelin Acetate, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 652
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 460 more

Conditions: Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
Interventions: Ubamatamab, Marlotamig, Sarilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Birmingham, Alabama • Goodyear, Arizona • Irvine, California + 14 more

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF); Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 30
States / cities: Palo Alto, California • San Francisco, California • Miami, Florida + 23 more

Conditions: Intradialytic Hypotension
Interventions: Icatibant, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions: UGN-103; Drug
Lead sponsor: UroGen Pharma Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 17
States / cities: Loma Linda, California • San Diego, California • Washington D.C., District of Columbia + 12 more

Conditions: Coronary Artery Disease
Interventions: Virtue Sirolimus AngioInfusion Balloon, AGENT™ Paclitaxel Drug-Coated Balloon; Device
Lead sponsor: Orchestra BioMed, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 22
States / cities: Phoenix, Arizona • Gainesville, Florida • Hollywood, Florida + 18 more

Clinical trials in Nashville, Tennessee

Filter and sort this location

Institutions in Nashville

Live official records

A Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter (AUS)

CBT Enhanced With Social Cognitive Training vs. CBT Only With Depressed Youth

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

Virtue® SAB in the Treatment of Coronary ISR Trial